Optimizing the antipsychotic potency of olanzapine by augmentation: A critical review;Optimierung der antipsychotischen therapie mit olanzapin durch augmentationsstrategien: Eine kritische literaturübersicht

Psychiatrische Praxis

Volumn 33, Issue 6, 2006, Pages 261-268

  Zink, Mathias ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; GENERIC DRUG; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; SULPIRIDE;

CLINICAL FEATURE; CLINICAL TRIAL; DATA BASE; DEPRESSION; DRUG POTENCY; DRUG SCREENING; HUMAN; MONOTHERAPY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 33748570726     PISSN: 03034259     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-915471     Document Type: Review

References (83)

1. Lieberman JA, Golden R, Stroup S, McEvoy J. Drugs of the psychopharmacological revolution in clinical psychiatry. Psychiatric Serv 2000; 51: 1254-1258
2. Miyamato S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10: 79-104
3. Sethi KD. Movement disorders induced by dopamine blocking agents. Sem Neurology 2001; 21: 59-68
4. Hellewell JS. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry 1999; 60, Suppl 23: 14-19
5. Young CR, Longhurst JG, Bowers Jr MB, Mazure CM. The expanding indications for clozapine. Exp Clin Psychopharmacol 1997; 5: 216-234
6. Buchanan RW. Clozapine: efficacy and safety. Schizophr Bull 1995; 21: 579-591
7. Young CR, Bowers Jr MB, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998; 24: 381-390
8. Miller DD. Review and management of clozapine side effects. J Clin Psychiatry 2000; 61, Suppl 8: 14-17; discussion 18-19
9. Stephenson CM, Pilowsky LS. Psychopharmacology of olanzapine. A review. Br J Psychiatry 1999; Suppl: 52-58
10. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25: 233-255
11. Frankle WG, Gil R, Hackett E, Mawlawi O, Zea-Ponce Y, Zhu Z et al. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacol 2004; 175: 473-480
12. Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001; 61: 111-161
13. Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochr Database Syst Rev, 2000: CD001359
14. Lutz R, Kohnlein O, Schmauss M, Messer T. Management of the atypical antipsychotic olanzapine in a clinical environment with particular regard to therapeutic drug monitoring (TDM) in a German State hospital. Psychiat Prax 2004; 31, Suppl 1: S181-S183
15. Kopf A, Koster J, Schulz A, Kromker H, Becker T. Life threatening neuroleptic malignant syndrome due to olanzapine. Psychiat Prax 2003; 30: 279-282
16. Kozian R. Olanzapine-induced diabetes mellitus. Psychiat Prax 2002; 29: 318-320
17. Conley RR, Meltzer HY. Adverse events related to olanzapine. J Clin Psychiatry 2000; 61, Suppl 8: 26-29, discussion 30
18. Thome J, Kopf D. Haematological abnormalities during treatment with atypical antipsychotics. Psychiat Prax 2005; 32: 167-171
19. McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 2003; 64: 984-989
20. Grohmann R, Engel RR, Geissler KH, Ruther E. Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 2004; 37, Suppl 1: S27-38
21. Lerner V, Libov I, Kotler M, Strous RD. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Progr Neuro-Psychopharmacol Biol Psychiatry 2004; 28: 89-98
22. Zink M, Dressing H. Clozapin-Augmentation mit atypischen Antipsychotika. Nervenarzt 2005; 76: 1092-1102
23. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997; 171: 569-573
24. Zink M, Knopf U, Henn FA, Thome J. Combination of clozapine and amisulpride in treatment-resistent schizophrenia - case reports and review of the literature. Pharmacopsychiatry 2004; 37: 26-31
25. Munro J, Matthiasson P, Osborne S, Travis M, Purcell S, Cobb AM et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004; 110: 292-298
26. Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005; 162: 130-136
27. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005; 66: 63-72
28. Stahl SM. Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr Scand 2002; 106: 321-322
29. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002; 106: 323-330
30. Zink M, Mase E, Dressing H. Ziprasidone-Augmentation of Clozapine. Psychiat Prax 2004; 31: 259-261
31. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. Am J Psychiatry 2004; 161: 700-706
32. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chemistry 2004; 11: 313-327
33. Zink M, Henn FA, Thome J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur Psychiatry 2004; 19: 56-58
34. Hiemke C, Peled A, Jabarin M, Hadjez J, Weigmann H, Hartter S et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 2002; 22: 502-506
35. Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R et al. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160: 297-302
36. Kotler IT, Ahmed B. Atypical (olanzapine) plus conventional (fluphenazine) neuroleptic treatment associated with the neuroleptic malignant syndrome. J Clin Psychopharmacol 2003; 23: 672-674
37. Kotler M, Strous RD, Reznik I, Shwartz S, Weizman A, Spivak B. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. Int Clin Psychopharmacol 2004; 19: 23-26
38. Raskin S, Durst R, Katz G, Zislin J. Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. J Clin Psychopharmacol 2000; 20: 500-503
39. Lerner V, Chudakova B, Kravets S, Polyakova I. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. Clin Neuropharmacol 2000; 23: 284-286
40. Abdullah N, Voronovitch L, Taylor S, Lippmann S. Olanzapine and haloperidol: potential for neutropenia? Psychosomatics 2003; 44: 83-84
41. Toki S, Morinobu S, Yoshino A, Yamawaki S. A case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics. [erratum appears in J Clin Psychiatry 2005 Jan; 66 (1): 138.] J Clin Psychiatry 2004; 65: 1576-1577
42. Mujica R, Weiden P. Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic. Am J Psychiatry 2001; 158: 650-651
43. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 165-171
44. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacol 2003; 28: 182-192
45. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G et al. D-Serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005; 57: 577-585
46. Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr Serv 2004; 55: 290-294
47. Cramer JA, Sernyak M. Results of a naturalistic study of treatment options: switching atypical antipsychotic drugs or augmenting with valproate. Clin Ther 2004; 26: 905-914
48. Rosaria Muscatello M, Pacetti M, Cacciola M, Torre D La, Zoccali R, D'Arrigo C et al. Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. Epilepsia 2005; 46: 771-774
49. Chiu CC, Lane HY, Huang MC, Liu HC, Jann MW, Hon YY et al. Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. J Clin Pharmacol 2004; 44: 1385-1390
50. Littrell KH, Petty RG, Hilligoss NM, Kirshner CD, Johnson CG. Valproate for hostility in schizophrenia patients. J Clin Psychiatry 2004; 65: 134
51. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004; 65: 903-907
52. Vieta E, Sanchez-Moreno J, Goikolea JM, Colom F, Martinez-Aran A, Benabarre A et al. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol 2004; 24: 374-378
53. Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 2004; 55: 553-555
54. Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 2004; 65: 565-568
55. Shelton RC. The combination of olanzapine and fluoxetine in mood disorders. Expert Op Pharmacotherapy 2003; 4: 1175-1183
56. Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Campen LE Van et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004; 24: 365-373
57. Corya SA, Andersen SW, Detke HC, Kelly LS, Campen LE van, Sanger TM et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. [erratum appears in J Clin Psychiatry 2004 Feb; 65 (2): 279.] J Clin Psychiatry 2003; 64: 1349-1356
58. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar 1 depression. [erratum appears in Arch Gen Psychiatry 2004 Feb; 61 (2): 176.] Arch Gen Psychiatry 2003; 60: 1079-1088
59. Weimer E, Braus DF, Cavus I, Thome J. Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression. Fortschr Neurol Psychiat 2002; 70: 210-217
60. Seager MA, Huff KD, Barth VN, Phebus LA, Rasmussen K. Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. Biol Psychiatry 2004; 55: 1103-1109
61. Ordway GA, Szebeni K. Effect of repeated treatment with olanzapine or olanzapine plus fluoxetine on tyrosine hydroxylase in the rat locus coeruleus. Int J Neuropsychopharmacol 2004; 7: 321-327
62. Maragnoli ME, Fumagalli F, Gennarelli M, Racagni G, Riva MA. Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biol Psychiatry 2004; 55: 1095-1102
63. Horowitz JM, Goyal A, Ramdeen N, Hallas BH, Horowitz AT, Torres G. Characterization of fluoxetine plus olanzapine treatment in rats: a behavior, endocrine, and immediate-early gene expression analysis. Synapse 2003; 50: 353-364
64. Kirk SL, Neill JC, Jones DN, Reynolds GP. Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. Eur J Pharmacol 2004; 505: 253-254
65. Deberdt W, Winokur A, Cavazzoni PA, Trzaskoma QN, Carlson CD, Bymaster FP et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 2005; 15: 13-21
66. Miller DE, Sebastian CS. Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report. J Clin Psychiatry 2005; 66: 269-270
67. Sernyak MJ, Rosenheck R. Clinician's reasons for antipsychotic coprescribing. J Clin Psychiatry 2004; 65: 1597-1600
68. Naber D, Riedel M, Klimke A, Vorbach E-U, Lambert M, Kühn K-U et al. Randomized double blind comparison of olanzapine versus clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 2005; 111: 106-115
69. Kelly DL, Richardson CM, Tamminga CA, Carpenter WT. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind, crossover study. J Clin Psychopharmacol 2003; 23: 668-670
70. Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes p450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 1996; 41: 181-186
71. Shen WW. The metabolism of atypical antipsychotic drugs: an update. Ann Clin Psychiatry 1999; 11: 145-158
72. Bergemann N, Frick A, Parzer P, Kopitz J. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry 2004; 37: 63-68
73. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003; 25: 46-53
74. Seger A, Lamberti JS. Priapism associated with polypharmacy. J Clin Psychiatry 2001; 62: 128
75. Pedrosa Gil F, Schneider C, Grohmann R, Ruther E. Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy. [erratum appears in Nervenarzt 2001 Nov; 72 (11): 878.] Nervenarzt 2001; 72: 729-733
76. Duggal HS. Aripirazole-olanzapine combination for treatment of schizophrenia. Can J Psychiatry - Rev Can Psychiatrie 2004; 49: 151
77. Dunkley MJ, Reveley MA. Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma. J Psychopharmacol 2005; 19: 97-101
78. Kapur S, Roy P, Daskalakis J, Remington G, Zipursky R. Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 2001; 158: 311-314
79. Matthiasson P, Erlandsson K, Costa DC, Waddington W, Visvikis D, Collum I et al. Amisulpride augmentation of clozapine and striatal dopamine d2 receptor binding potential. A 123-I-IBZM study. Schizophr Res 2003; 53: 208
80. Dursun SM, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol 2001; 15: 297-301
81. Takhar J. Pimozide augmentation in a patient with drug-resistant psychosis previously treated with olanzapine. J Psychiatry Neurosci 1999; 24: 248-249
82. Gupta S, Sonnenberg SJ, Frank B. Olanzapine augmentation of clozapine. Ann Clin Psychiatry 1998; 10: 113-115
83. Rhoads E. Polypharmacy of 2 atypical antipsychotics. J Clin Psychiatry 2000; 61: 678-680